Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer

D. M. Moreira, L. E. Howard, K. N. Sourbeer, H. S. Amarasekara, L. C. Chow, D. C. Cockrell, B. T. Hanyok, C. L. Pratson, W. J. Aronson, C. J. Kane, M. K. Terris, C. L. Amling, M. R. Cooperberg, A. Liede, S. J. Freedland

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background:To evaluate PSA levels and kinetic cutoffs to predict positive bone scans for men with non-metastatic castration-resistant prostate cancer (CRPC) from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort.Methods:Retrospective analysis of 531 bone scans of 312 clinically CRPC patients with no known metastases at baseline treated with a variety of primary treatment types in the SEARCH database. The association of patients' demographics, pathological features, PSA levels and kinetics with risk of a positive scan was tested using generalized estimating equations.Results:A total of 149 (28%) scans were positive. Positive scans were associated with younger age (odds ratio (OR)=0.98; P=0.014), higher Gleason scores (relative to Gleason 2-6, Gleason 3+4: OR=2.03, P=0.035; Gleason 4+3 and 8-10: OR=1.76, P=0.059), higher prescan PSA (OR=2.11; P<0.001), shorter prescan PSA doubling time (PSADT; OR=0.53; P<0.001), higher PSA velocity (OR=1.74; P<0.001) and more remote scan year (OR=0.92; P=0.004). Scan positivity was 6, 14, 29 and 57% for men with PSA<5, 5-14.9, 15-49.9 and ≥50 ng ml -1, respectively (P-trend <0.001). Men with PSADT ≥15, 9-14.9, 3-8.9 and <3 months had a scan positivity of 11, 22, 34 and 47%, correspondingly (P-trend <0.001). Tables were constructed using PSA and PSADT to predict the likelihood of a positive bone scan.Conclusions:PSA levels and kinetics were associated with positive bone scans. We developed tables to predict the risk of positive bone scans by PSA and PSADT. Combining PSA levels and kinetics may help select patients with CRPC for bone scans.

Original languageEnglish (US)
Pages (from-to)333-337
Number of pages5
JournalProstate Cancer and Prostatic Diseases
Volume18
Issue number4
DOIs
StatePublished - Dec 1 2015

Fingerprint

Castration
Prostatic Neoplasms
Odds Ratio
Bone and Bones
Cancer Care Facilities
Bone Neoplasms
Neoplasm Grading
Demography
Databases
Neoplasm Metastasis

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this

Moreira, D. M., Howard, L. E., Sourbeer, K. N., Amarasekara, H. S., Chow, L. C., Cockrell, D. C., ... Freedland, S. J. (2015). Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 18(4), 333-337. https://doi.org/10.1038/pcan.2015.25

Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. / Moreira, D. M.; Howard, L. E.; Sourbeer, K. N.; Amarasekara, H. S.; Chow, L. C.; Cockrell, D. C.; Hanyok, B. T.; Pratson, C. L.; Aronson, W. J.; Kane, C. J.; Terris, M. K.; Amling, C. L.; Cooperberg, M. R.; Liede, A.; Freedland, S. J.

In: Prostate Cancer and Prostatic Diseases, Vol. 18, No. 4, 01.12.2015, p. 333-337.

Research output: Contribution to journalArticle

Moreira, DM, Howard, LE, Sourbeer, KN, Amarasekara, HS, Chow, LC, Cockrell, DC, Hanyok, BT, Pratson, CL, Aronson, WJ, Kane, CJ, Terris, MK, Amling, CL, Cooperberg, MR, Liede, A & Freedland, SJ 2015, 'Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer', Prostate Cancer and Prostatic Diseases, vol. 18, no. 4, pp. 333-337. https://doi.org/10.1038/pcan.2015.25
Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC et al. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 2015 Dec 1;18(4):333-337. https://doi.org/10.1038/pcan.2015.25
Moreira, D. M. ; Howard, L. E. ; Sourbeer, K. N. ; Amarasekara, H. S. ; Chow, L. C. ; Cockrell, D. C. ; Hanyok, B. T. ; Pratson, C. L. ; Aronson, W. J. ; Kane, C. J. ; Terris, M. K. ; Amling, C. L. ; Cooperberg, M. R. ; Liede, A. ; Freedland, S. J. / Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. In: Prostate Cancer and Prostatic Diseases. 2015 ; Vol. 18, No. 4. pp. 333-337.
@article{6a940c7c21f8441aa571fa97963ab2c6,
title = "Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer",
abstract = "Background:To evaluate PSA levels and kinetic cutoffs to predict positive bone scans for men with non-metastatic castration-resistant prostate cancer (CRPC) from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort.Methods:Retrospective analysis of 531 bone scans of 312 clinically CRPC patients with no known metastases at baseline treated with a variety of primary treatment types in the SEARCH database. The association of patients' demographics, pathological features, PSA levels and kinetics with risk of a positive scan was tested using generalized estimating equations.Results:A total of 149 (28{\%}) scans were positive. Positive scans were associated with younger age (odds ratio (OR)=0.98; P=0.014), higher Gleason scores (relative to Gleason 2-6, Gleason 3+4: OR=2.03, P=0.035; Gleason 4+3 and 8-10: OR=1.76, P=0.059), higher prescan PSA (OR=2.11; P<0.001), shorter prescan PSA doubling time (PSADT; OR=0.53; P<0.001), higher PSA velocity (OR=1.74; P<0.001) and more remote scan year (OR=0.92; P=0.004). Scan positivity was 6, 14, 29 and 57{\%} for men with PSA<5, 5-14.9, 15-49.9 and ≥50 ng ml -1, respectively (P-trend <0.001). Men with PSADT ≥15, 9-14.9, 3-8.9 and <3 months had a scan positivity of 11, 22, 34 and 47{\%}, correspondingly (P-trend <0.001). Tables were constructed using PSA and PSADT to predict the likelihood of a positive bone scan.Conclusions:PSA levels and kinetics were associated with positive bone scans. We developed tables to predict the risk of positive bone scans by PSA and PSADT. Combining PSA levels and kinetics may help select patients with CRPC for bone scans.",
author = "Moreira, {D. M.} and Howard, {L. E.} and Sourbeer, {K. N.} and Amarasekara, {H. S.} and Chow, {L. C.} and Cockrell, {D. C.} and Hanyok, {B. T.} and Pratson, {C. L.} and Aronson, {W. J.} and Kane, {C. J.} and Terris, {M. K.} and Amling, {C. L.} and Cooperberg, {M. R.} and A. Liede and Freedland, {S. J.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1038/pcan.2015.25",
language = "English (US)",
volume = "18",
pages = "333--337",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer

AU - Moreira, D. M.

AU - Howard, L. E.

AU - Sourbeer, K. N.

AU - Amarasekara, H. S.

AU - Chow, L. C.

AU - Cockrell, D. C.

AU - Hanyok, B. T.

AU - Pratson, C. L.

AU - Aronson, W. J.

AU - Kane, C. J.

AU - Terris, M. K.

AU - Amling, C. L.

AU - Cooperberg, M. R.

AU - Liede, A.

AU - Freedland, S. J.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background:To evaluate PSA levels and kinetic cutoffs to predict positive bone scans for men with non-metastatic castration-resistant prostate cancer (CRPC) from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort.Methods:Retrospective analysis of 531 bone scans of 312 clinically CRPC patients with no known metastases at baseline treated with a variety of primary treatment types in the SEARCH database. The association of patients' demographics, pathological features, PSA levels and kinetics with risk of a positive scan was tested using generalized estimating equations.Results:A total of 149 (28%) scans were positive. Positive scans were associated with younger age (odds ratio (OR)=0.98; P=0.014), higher Gleason scores (relative to Gleason 2-6, Gleason 3+4: OR=2.03, P=0.035; Gleason 4+3 and 8-10: OR=1.76, P=0.059), higher prescan PSA (OR=2.11; P<0.001), shorter prescan PSA doubling time (PSADT; OR=0.53; P<0.001), higher PSA velocity (OR=1.74; P<0.001) and more remote scan year (OR=0.92; P=0.004). Scan positivity was 6, 14, 29 and 57% for men with PSA<5, 5-14.9, 15-49.9 and ≥50 ng ml -1, respectively (P-trend <0.001). Men with PSADT ≥15, 9-14.9, 3-8.9 and <3 months had a scan positivity of 11, 22, 34 and 47%, correspondingly (P-trend <0.001). Tables were constructed using PSA and PSADT to predict the likelihood of a positive bone scan.Conclusions:PSA levels and kinetics were associated with positive bone scans. We developed tables to predict the risk of positive bone scans by PSA and PSADT. Combining PSA levels and kinetics may help select patients with CRPC for bone scans.

AB - Background:To evaluate PSA levels and kinetic cutoffs to predict positive bone scans for men with non-metastatic castration-resistant prostate cancer (CRPC) from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort.Methods:Retrospective analysis of 531 bone scans of 312 clinically CRPC patients with no known metastases at baseline treated with a variety of primary treatment types in the SEARCH database. The association of patients' demographics, pathological features, PSA levels and kinetics with risk of a positive scan was tested using generalized estimating equations.Results:A total of 149 (28%) scans were positive. Positive scans were associated with younger age (odds ratio (OR)=0.98; P=0.014), higher Gleason scores (relative to Gleason 2-6, Gleason 3+4: OR=2.03, P=0.035; Gleason 4+3 and 8-10: OR=1.76, P=0.059), higher prescan PSA (OR=2.11; P<0.001), shorter prescan PSA doubling time (PSADT; OR=0.53; P<0.001), higher PSA velocity (OR=1.74; P<0.001) and more remote scan year (OR=0.92; P=0.004). Scan positivity was 6, 14, 29 and 57% for men with PSA<5, 5-14.9, 15-49.9 and ≥50 ng ml -1, respectively (P-trend <0.001). Men with PSADT ≥15, 9-14.9, 3-8.9 and <3 months had a scan positivity of 11, 22, 34 and 47%, correspondingly (P-trend <0.001). Tables were constructed using PSA and PSADT to predict the likelihood of a positive bone scan.Conclusions:PSA levels and kinetics were associated with positive bone scans. We developed tables to predict the risk of positive bone scans by PSA and PSADT. Combining PSA levels and kinetics may help select patients with CRPC for bone scans.

UR - http://www.scopus.com/inward/record.url?scp=84946717961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946717961&partnerID=8YFLogxK

U2 - 10.1038/pcan.2015.25

DO - 10.1038/pcan.2015.25

M3 - Article

C2 - 26171882

AN - SCOPUS:84946717961

VL - 18

SP - 333

EP - 337

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 4

ER -